Management of Acute Musculoskeletal Pain

Combination Therapy for Acute Musculoskeletal Conditions

The American College of Physicians guidelines position NSAIDs as first-line therapy and muscle relaxants as second-line options for short-term relief, with combination therapy being a reasonable approach when monotherapy is insufficient 1

Co-prescribing opioids with benzodiazepines increases mortality risk 3- to 10-fold compared to opioids alone, due to potentiation of respiratory depression 2, 3, 4
The FDA issued a black box warning in 2016 specifically against co-prescribing opioids and benzodiazepines 2, 4
Emergency medicine guidelines recommend against routinely combining opioids with muscle relaxants/sedative-hypnotics when discharging patients 2, 3

Start with NSAID monotherapy, and add a non-benzodiazepine muscle relaxant if NSAID alone provides insufficient relief 1
Prescribe for short duration only, typically 7-14 days maximum, as muscle relaxants are effective for short-term relief but associated with sedation and other CNS side effects 5, 6

Assess cardiovascular and gastrointestinal risk factors before prescribing NSAIDs, and use the lowest effective dose for the shortest necessary duration 1, 7
Add a proton pump inhibitor for patients at high GI risk, and monitor renal function and blood pressure 1, 7
Warn patients about sedation and drowsiness when prescribing muscle relaxants, which occur in approximately 49% of patients, and advise against driving or operating machinery until tolerance to sedative effects is established 1

Do not assume all muscle relaxants are benzodiazepines—non-benzodiazepine agents like cyclobenzaprine, methocarbamol, and tizanidine are preferred for musculoskeletal pain 5, 6
Do not prescribe muscle relaxants for chronic pain, as evidence supports their use only for acute pain, and do not combine muscle relaxants with opioids routinely, as this combination carries significant mortality risk and lacks evidence of superior efficacy compared to safer alternatives 2, 3, 4, 5

Avoid routine co‑prescription of opioids with benzodiazepines or other muscle‑relaxant/sedative‑hypnotic agents – the American College of Emergency Physicians (ACEP) recommends against this practice because of significant safety concerns. Strong recommendation based on multiple 2020 emergency‑medicine studies. [8][9]10
Co‑prescribing opioids with benzodiazepines raises mortality risk 3‑ to 10‑fold compared with opioids alone, due to potentiated respiratory depression. High‑quality observational evidence supports this magnitude of risk. 10
The U.S. FDA issued a black‑box warning in 2016 specifically prohibiting the combined use of opioids and benzodiazepines. Regulatory authority underscores the seriousness of the interaction. 9
No evidence shows superior analgesic efficacy for the opioid + benzodiazepine combination over safer alternatives (e.g., opioid + NSAID or NSAID alone). Moderate‑quality comparative data indicate no added benefit. [8][9]

Muscle‑relaxants should be limited to acute pain conditions (e.g., painful muscle spasm) and prescribed for a short course of 7–14 days maximum. This recommendation is supported by systematic reviews of acute‑pain trials. Moderate‑quality evidence. [11][12]

Adding a non‑benzodiazepine muscle relaxant to NSAID therapy does not outperform NSAID monotherapy for acute low‑back pain. Meta‑analyses of randomized trials show no clinically meaningful advantage. Moderate‑quality meta‑analytic evidence. 8

Muscle‑relaxants are associated with a high incidence of adverse effects, most notably sedation, drowsiness, and dizziness. Consistent findings across multiple trials. [11][12]
Cochrane systematic review (2012) confirms that muscle‑relaxants provide short‑term symptomatic relief in acute musculoskeletal pain but are linked to a high rate of adverse events. High‑quality systematic review. [11][12]